A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions

Birgit M. Reipert; Axel Schoppmann; Hans Peter Schwarz

doi:10.1055/s-0037-1613416

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2003; 89(06): 1110-1112
DOI: 10.1055/s-0037-1613416

Letters to the Editor

Schattauer GmbH

A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions

Authors

Birgit M. Reipert
Axel Schoppmann
Hans Peter Schwarz

Abstract

Volltext

Referenzen

References
1 Kreuz W, Auerswald G, Budde U, Lenk H, Klose H. Inhibitor incidence in previously untreated patients (PUBs) with hemophilia A and B - a prospective multicenter study of the GTH. 46th Annual Meeting of the German Society for Thrombosis and Haemostasis (GTH), February 2002, Erfurt, Germany. Ann Hematol 2002; 81 (Suppl. 01) Suppl A48
2 Behrmann M, Pasi J, Saint-Remy JMS, Kotitschke R, Kloft M. Von Willebrand Factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
3 Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian Jr HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
4 Muchitsch EM, Turecek PL, Zimmermann K. et al. Phenotypic expression of murine hemophilia (letter). Thromb Haemost 1999; 82: 1371-3.
5 Qian J, Borovok M, Bi L, Kazazian Jr HH, Hoyer LW. Inhibitor development and T cell response to human factor VIII in murine haemophilia A. Thromb Haemost 1999; 81: 240-4.
6 Reipert BM, Ahmad RU, Turecek PL, Schwarz HR. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-32.
7 Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW. Conti-Fine BM: Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125 33
8 Sasgary M, Ahmad RU, Schwarz HP, Turecek PL and Reipert BM. Single cell analysis of factor VHI-specific T-cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.
9 Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL, Reipert BM. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-45.
10 Reipert BM, Schwarz HR. What can we learn from the immune response to human factor VIII in a mouse model of murine hemophilia A ? (letter) Thromb Haemost. 2002; 88: 374-5.
11 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
12 Qian J, Burkly LC, Smith EP, Ferrant JL. et al. Role of CD154 in the secondary immune response: the reduction of preexisting splenic germinal centers and anti-factor VIII inhibitor titers. Eur J Immunol 2000; 30: 2548-54.
13 Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance Thromb Haemost. 2001; 86: 1345-52.
14 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
15 Schwaab R, Brackmann HH, Meyer C. et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
16 Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in hemophilia A. Haemophilia 1998; 4: 543-5.
17 Fakharzadeh SS, Kazazian HH. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Sem Thromb Hemost 2000; 26: 167-71.
18 Adler FL. Competition of antigens. Progr Allergy 1964; 8: 41-57.
19 Taussig MJ. Antigenic competition. Curr Top Microbiol Immunol 1973; 60: 125-74.
20 Pross HF, Eidinger D. Antigenic competition: a review of nonspecific antigen-induced suppression. Adv Immunol 1974; 18: 133-68.
21 Hunt JD, Jackson DC, Wood PR, Stewart DJ, Brown LE. Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine 1995; 17: 1649-57.
22 Babbitt BP, Matsueda G, Haber E, Unanue ER, Allen PM. Antigenic competition at the level of peptide-Ia binding. PNAS 1986; 83: 4509-13.
23 Adorini L, Nagy ZA. Peptide competition for antigen presentation. Immunol Today 1990; 11: 21-4.
24 Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus and surface glycoproteins. PNAS 1997; 84: 6869-73.
25 Smith AL, Wikstrom ME, Fazekas de St. Groth B. Visualizing T cell competition for peptide/MHC complexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000; 13: 783-94.
26 Kawasaki T, Kaida T, Arnout J, Vermylen J, Holyaerts MF. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost 1999; 81: 306-11.